Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02117076
Other study ID # RLS and Gabapentin or Horizant
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date April 2014
Est. completion date June 2016

Study information

Verified date November 2021
Source University of South Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.


Description:

The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome. Subjects will be randomized to gabapentin (IR) or Horizant™ (ER). Dosing will be blinded to both patient and study team members. Once study medication dosing has been optimized, subjects will then remain on a stable dose for six weeks until study endpoint, after which subjects will be down-titrated off of study medications.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Outpatients with a diagnosis of primary restless leg syndrome using the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria8. 2. RLS symptoms = 15 nights of the month prior to study enrollment and for = 4 of 7 consecutive nights in the week prior to study enrollment (if untreated). 3. Age 18 years to 80 years. 4. International Restless Legs Scale (IRLS) Total severity score of = 15 (moderate to severe severity). 8 5. Had significant sleep disturbance on item 4 of IRLS.8 6. Women of child-bearing potential must use a reliable method of contraception. 7. Informed consent. Subject must be willing and able to complete all study procedures. Exclusion Criteria: 1. Any illness that in the investigator's opinion preclude participation in this study. 2. Subjects with non-RLS-related sleep disorders (e.g., sleep apnea) 3. Subjects with neurological diseases or movement disorders other than RLS (e.g., diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesias, and dystonias) 4. Pregnancy or lactation. 5. Concurrent participation in another clinical study. 6. Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini-Mental State Examination scores less than 27). 7. Legal incapacity or limited legal capacity. 8. History of RLS symptom augmentation or early-morning rebound with previous dopamine-agonist treatment. 9. Clinically significant abnormalities in renal function. 3,8,10 10. Presence of severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease. 11. Concomitant treatment with drugs known to affect sleep/wake, RLS or periodic limb movements, including antidepressants. Subjects receiving treatment for RLS at screening will be required to discontinue and wash out for a minimum of 5 half-lives. 12. Body mass index greater than 34 kg/m2.

Study Design


Intervention

Drug:
Gabapentin immediate release
up to 1200 mg per day
Gabapentin enacarbil extended release
up to 1200 mg per day

Locations

Country Name City State
United States University of South Florida Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Theresa Zesiewicz, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Medical Outcomes Study (MOS) Sleep Scale The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of sleep and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 ( 1 = 0-15 min to more than 60 min) and Questions 2 to 12 are scored on a scale of 1 to 6 (1 = all of the time to 6 = none of the time. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7, and 8 and ranges from 0 to 100, where higher scores indicate greater sleep disturbance. Baseline, day 35, day 54
Primary International Restless Leg Syndrome Rating Scale (IRLS) The IRLS is a measure of severity of Restless Legs Syndrome. It includes 10 items, measured on a scale of 0-4. A score of 1-10 indicates mild severity, 11-20 indicates moderate severity, 21-30 is severe and 31-40 is very severe. Primary outcome is the difference in IRLS scores for each of the treatment regimens.
from 0 to 4.
10 weeks
Secondary Restless Leg Syndrome Quality of Life Scale (RLSQoL) The Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) assesses the impact of RLS on daily life, emotional well-being, social life, and work life. Baseline, day 35, day 54.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01931878 - Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome. Phase 2
Completed NCT01672502 - Fire Fighter Fatigue Management Program: Operation Fight Fatigue N/A
Completed NCT02085720 - Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance N/A
Completed NCT03337529 - Restless Legs Syndrome in Hemodialysis Patients N/A
Completed NCT01245777 - Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Phase 4
Completed NCT01617044 - Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome Phase 2
Recruiting NCT02016638 - Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes N/A
Completed NCT01988129 - Fire Fighter Fatigue Management Program: Operation Healthy Sleep N/A
Completed NCT00949858 - New Data Analysis Methods for Actigraphy in Sleep Medicine N/A
Completed NCT03818243 - Circadian Character of Food Compulsions and Impulses Control Disorders in Parkinsonian Patients With and Without Resting Leg Syndrome N/A
Completed NCT00872248 - Neuraxial Anesthesia and Restless Leg Syndromes in Cesarean N/A
Completed NCT00673088 - A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions N/A
Completed NCT00674310 - A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions N/A
Completed NCT01538147 - Restless Leg Syndrome and Severe Preeclampsia N/A
Completed NCT02386423 - RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome N/A
Recruiting NCT06233773 - The Effect of Kinesio Taping and Manual Lymph Drainage on Pregnant Women With Restless Legs Syndrome N/A